MRD检测新靶点在急性髓系白血病复发中的研究现状  

Research Status of New Targets MRD Detection in Acute Myeloid Leukemia Recurrence——Review

作　　者：张任乐 周兰霞[2] 田红娟 赵丽[1] ZHANG Ren-Le;ZHOU Lan-Xia;TIAN Hong-Juan;ZHAO Li(The First Clinical Medicine College of Lanzhou University;Central Laboratory of The First Hospital of Lanzhou University,Lanzhou 730000,Gansu Province,China)

机构地区：[1]兰州大学第一临床医学院 [2]兰州大学第一医院中心实验室,甘肃兰州730000

出　　处：《中国实验血液学杂志》2021年第1期293-296,共4页Journal of Experimental Hematology

摘　　要：大多数急性髓系白血病(AML)患者虽然在标准化疗方案诱导下可达到完全缓解(CR),但缓解后的复发率仍高居不下,最关键的原因在于其在细胞遗传学和分子生物学方面的高度异质性。有证据表明,微小残留病(MRD)与疾病复发密切相关,因此,寻找特定的遗传学和分子生物学改变作为MRD检测的新靶点成为近些年的研究热点。本文旨在阐述AML复发与特定分子事件MRD检测的内在联系,并根据最新指南对这些新靶点在MRD检测中的应用及其靶向治疗进行综述,以期在CR期给予最优治疗方案。Although most acute myeloid leukemia(AML)patients can achieve complete remission(CR)induced by standardized chemotherapy,but the relapse rate after remission remains high.The key reason is its high heterogeneity in cytogenetics and molecular biology.There are evidences show that minimal residual disease(MRD)is closely associated with disease recurrence,so that,finding specific genetic and molecular biological changes as new targets for MRD detection has become a research hotspot in recent years.In this review the intrinsic relationship between relapse of AML and MRD detection of specific molecular events,the application of these new targets in MRD detection and their targeted therapies according to the latest guidelines,so as to achieve the optimal treatment in CR phase.

关 键 词：急性髓系白血病 复发 微小残留病 新靶点 靶向治疗 

分 类 号：R733.71[医药卫生—肿瘤]